Treatment of postsclerotherapy esophageal ulcers with sucralfate.
Deep ulceration of the esophagus is the most common significant complication of endoscopic injection sclerosis of varices. Four patients with persistent bleeding from sclerotherapy-induced ulcers were treated with sucralfate. Adherence of sucralfate to the ulcerated areas was demonstrated endoscopically, and bleeding stopped in three patients. Sucralfate may be useful in the treatment of esophageal ulcers caused by sclerotherapy.
D000535:Aluminum / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004935:Esophageal Diseases / Q000188:drug therapy / Q000209:etiology*; D004945:Esophagoscopy; D005227:Fatty Acids / Q000009:adverse effects*; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D012976:Sodium Morrhuate / Q000009:adverse effects*; D013392:Sucralfate; D014456:Ulcer / Q000188:drug therapy / Q000209:etiology
D000897:Anti-Ulcer Agents; D005227:Fatty Acids; D013392:Sucralfate; D012976:Sodium Morrhuate; D000535:Aluminum